0001654954-22-014263.txt : 20221026 0001654954-22-014263.hdr.sgml : 20221026 20221026214120 ACCESSION NUMBER: 0001654954-22-014263 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221026 FILED AS OF DATE: 20221026 DATE AS OF CHANGE: 20221026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: tsai chun-hsien CENTRAL INDEX KEY: 0001859363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 221334654 MAIL ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-10-26 0001014763 Ainos, Inc. AIMD 0001859363 tsai chun-hsien 8880 RIO SAN DIEGO DRIVE, SUITE 800 SAN DIEGO CA 92108 true true CEO, PRESIDENT, CHAIRMAN Common Stock 2022-10-26 4 A false 333333 1.89 A 355599 D Common Stock 22266 D RSU 1.89 2022-10-26 4 C false 5000000 1.89 D 2022-09-30 2022-10-26 COMMON 333333 0 D RSU 2022-10-24 4 A false 50000 D COMMON 50000 50000 D The amount of common stock previously reported totaling 333,986 shares is hereby adjusted to 22,266 shares giving effect to a 15-to-1 Reverse Stock Split made effective on August 8, 2022 (the "Reverse Stock Split"). This reported transaction represents the conversion of 5,000,000 Restricted Stock Units (the "RSUs") adjusted to 333,000 shares giving effect to the Reverse Stock Split. The RSUs were originally granted pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") under the Company's 2021 Stock Incentive Plan. The converted shares underlying the RSUs vested on September 30, 2022 and may not be sold within 6 months of the grant date. This reported transaction represents the settlement of 5,000,000 RSUs adjusted to 333,333 common stock after giving effect the Reverse Stock Split. This reported transaction represents the granting of 50,000 Restricted Stock Units (the "RSUs"). The RSUs were originally authorized pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") and under the Company's 2021 Stock Incentive Plan. The RSUs will vest in increments of 15% on 4/24/23 and 10/24/23, 30% on 10/24/24 and 40% on 10/24/25, subject to normal and customary termination events. /s/ John Junyong Lee POA for Chun-Hsien Tsai 2022-10-26